AcquisitionOther
SYNLOGIC, INC. acquired target
Public M&A record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
SYNLOGIC, INC. -> target · $278 million
(“Caldera”), a privately held clinical-stage biotechnology company developing CLD-423, a potential first-in-class TL1A x IL-23p19 bispecific antibody for inflammatory bowel disease (IBD) and other immune-mediated diseases, today announced that they have entere
Open source record (SEC) ↗